Neuland Laboratories Ltd. (IN:NEULANDLAB)
:NEULANDLAB
Want to see IN:NEULANDLAB full AI Analyst Report?
NEULANDLAB Stock Chart & Stats
₹15265.60
₹591.15(4.14%)
At close: 4:00 PM EST
₹15265.60
₹591.15(4.14%)
Day’s Range― - ―
52-Week Range₹10,598.05 - ₹19,748.40
Previous CloseN/A
Volume58.52K
Average Volume (3M)2.41K
Market Cap
₹187.99B
Enterprise Value₹190.27B
Total Cash (Recent Filing)₹1.80B
Total Debt (Recent Filing)₹2.65B
Price to Earnings (P/E)120.0
Beta1.22
Next Earnings
May 12, 2026EPS Estimate
78.16Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)37.00
Shares Outstanding12,829,889
10 Day Avg. Volume1,318
30 Day Avg. Volume2,408
Financial Highlights & Ratios
PEG Ratio-4.25
Price to Book (P/B)9.66
Price to Sales (P/S)10.27
P/FCF Ratio132.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)338.23
Revenue Forecast (FY)₹22.42B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA robust balance sheet with a high equity ratio and prudent leverage improves resilience to industry cycles, supports capex for facility upgrades and regulatory compliance, and reduces refinancing risk. This stability underpins long-term supply commitments to regulated markets.
Revenue Growth & Improving Gross MarginsSustained revenue growth combined with rising gross margins indicates scalable manufacturing and better cost control. For an API/CDMO, expanding top-line with margin improvement signals stronger pricing power, process efficiencies and competitiveness in complex chemistries over the medium term.
Consistent Operating Cash GenerationReliable operating cash flow supports working capital needs, funds development-to-commercial transitions in CDMO projects, and allows reinvestment without reliance on markets. Even with some FCF variability, historical improvement provides financial flexibility for growth investments.
Bears Say
Earnings VolatilityA steep decline in EPS growth signals earnings instability that may stem from margin swings, project timing or one-offs. Persistent EPS volatility weakens predictability of cash available for reinvestment, may constrain strategic spending, and complicates long-term planning for clients and investors.
Rising Debt TrendAn upward trend in total debt, even from a solid base, raises leverage and interest exposure over time. If growth or margin pressures persist, higher debt amplifies refinancing and liquidity risk, reducing headroom for capex or R&D critical to retaining complex-chemistry customers.
Profitability & FCF VariabilityMixed net margins and recent FCF decline indicate underlying earnings and cash conversion sensitivity to product mix, pricing or cycle timing. This variability can strain funding for long-lead CDMO projects, limit buffer for regulatory investments, and complicate long-term margin sustainability.
Neuland Laboratories Ltd. News
NEULANDLAB FAQ
What was Neuland Laboratories Ltd.’s price range in the past 12 months?
Neuland Laboratories Ltd. lowest stock price was ₹10598.05 and its highest was ₹19748.40 in the past 12 months.
What is Neuland Laboratories Ltd.’s market cap?
Neuland Laboratories Ltd.’s market cap is ₹187.99B.
When is Neuland Laboratories Ltd.’s upcoming earnings report date?
Neuland Laboratories Ltd.’s upcoming earnings report date is May 12, 2026 which is in 12 days.
How were Neuland Laboratories Ltd.’s earnings last quarter?
Neuland Laboratories Ltd. released its earnings results on Feb 09, 2026. The company reported ₹37 earnings per share for the quarter, missing the consensus estimate of ₹56.52 by -₹19.52.
Is Neuland Laboratories Ltd. overvalued?
According to Wall Street analysts Neuland Laboratories Ltd.’s price is currently Overvalued.
Does Neuland Laboratories Ltd. pay dividends?
Neuland Laboratories Ltd. pays a Annually dividend of ₹12 which represents an annual dividend yield of 0.08%. See more information on Neuland Laboratories Ltd. dividends here
What is Neuland Laboratories Ltd.’s EPS estimate?
Neuland Laboratories Ltd.’s EPS estimate is 78.16.
How many shares outstanding does Neuland Laboratories Ltd. have?
Neuland Laboratories Ltd. has 12,829,889 shares outstanding.
What happened to Neuland Laboratories Ltd.’s price movement after its last earnings report?
Neuland Laboratories Ltd. reported an EPS of ₹37 in its last earnings report, missing expectations of ₹56.52. Following the earnings report the stock price went up 6.856%.
Which hedge fund is a major shareholder of Neuland Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:NEULANDLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neuland Laboratories Ltd.
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was incorporated in 1984 and is headquartered in Hyderabad, India.
Technical Analysis
Caplin Point Laboratories Limited
―
―
Granules India Limited
―
Marksans Pharma Limited
―
NATCO Pharma Limited
―